WSO - April 2024 - 386

386
International Journal of Stroke 19(4)
13. McCabe JJ, Camps-Renom P, Giannotti N, et al. Carotid
plaque inflammation imaged by PET and prediction of recurrent
stroke at 5 years. Neurology 2021; 97: e2282-e2291.
14. Ornello R, Degan D, Tiseo C, et al. Distribution and temporal
trends from 1993 to 2015 of ischemic stroke subtypes: a systematic
review and meta-analysis. Stroke 2018; 49: 814-819.
15. Jacob MA, Cai M, van de Donk V, et al. Cerebral small vessel
disease progression and the risk of dementia: a 14-year
follow-up study. Am J Psychiatry 2023; 180: 508-518.
16. Pinter D, Ritchie SJ, Doubal F, et al. Impact of small vessel
disease in the brain on gait and balance. Sci Rep 2017; 7:
41637.
17. Walsh J, Tozer DJ, Sari H, et al. Microglial activation and
blood-brain barrier permeability in cerebral small vessel disease.
Brain 2021; 144: 1361-1371.
18. Low A, Mak E, Rowe JB, Markus HS and O'Brien JT.
Inflammation and cerebral small vessel disease: a systematic
review. Ageing Res Rev 2019; 53: 100916.
19. Jalal FY, Yang Y, Thompson JF, Roitbak T and Rosenberg GA.
Hypoxia-induced neuroinflammatory white-matter injury
reduced by minocycline in SHR/SP. J Cereb Blood Flow
Metab 2015; 35: 1145-1153.
20. Hoshi T, Kitagawa K, Yamagami H, Furukado S, Hougaku H
and Hori M. Relations of serum high-sensitivity C-reactive
protein and interleukin-6 levels with silent brain infarction.
Stroke 2005; 36: 768-772.
21. Walker KA, Windham BG, Power MC, et al. The association
of mid-to late-life systemic inflammation with white matter
structure in older adults: the atherosclerosis risk in communities
study. Neurobiol Aging 2018; 68: 26-33.
22. Elkind MS, Luna JM, McClure LA, et al. C-reactive protein
as a prognostic marker after lacunar stroke: levels of inflammatory
markers in the treatment of stroke study. Stroke 2014;
45: 707-716.
23. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB,
Gordon DL and Marsh EE 3rd. Classification of subtype of
acute ischemic stroke. Definitions for use in a multicenter
clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment.
Stroke 1993; 24: 35-41.
24. Hu YF, Chen YJ, Lin YJ and Chen SA. Inflammation and the
pathogenesis of atrial fibrillation. Nat Rev Cardiol 2015; 12:
230-243.
25. Aviles RJ, Martin DO,
Apperson-Hansen C, et al.
Inflammation as a risk factor for atrial fibrillation. Circulation
2003; 108: 3006-3010.
26. Lip GY, Patel JV, Hughes E and Hart RG. High-sensitivity
C-reactive protein and soluble CD40 ligand as indices of
inflammation and platelet activation in 880 patients with nonvalvular
atrial fibrillation: relationship to stroke risk factors,
stroke risk stratification schema, and prognosis. Stroke 2007;
38: 1229-1237.
27. Aulin J, Siegbahn A, Hijazi Z, et al. Interleukin-6 and
C-reactive protein and risk for death and cardiovascular
events in patients with atrial fibrillation. Am Heart J 2015;
170: 1151-1160.
28. Kallergis EM, Manios EG, Kanoupakis EM, et al. The role of
the post-cardioversion time course of hs-CRP levels in clarifying
the relationship between inflammation and persistence of
atrial fibrillation. Heart 2008; 94: 200-204.
International Journal of Stroke, 19(4)
29. Xie W, Santulli G, Reiken SR, Yuan Q, Osborne BW, Chen
BX and Marks AR. Mitochondrial oxidative stress promotes
atrial fibrillation. Sci Rep 2015; 5: 11427.
30. Lee GS, Subramanian N, Kim AI, et al. The calcium-sensing
receptor regulates the NLRP3 inflammasome through Ca2+
and cAMP. Nature 2012; 492: 123-127.
31. Yao C, Veleva T, Scott LJ, et al. Enhanced cardiomyocyte
NLRP3 inflammasome signaling promotes atrial fibrillation.
Circulation 2018; 138: 2227-2242.
32. Kommu S and Arepally S. The effect of colchicine on atrial
fibrillation: a systematic review and meta-analysis. Cureus
2023; 15: e35120.
33. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson
SG, Collins R and Danesh J. C-reactive protein concentration
and risk of coronary heart disease, stroke, and mortality: an
individual participant meta-analysis. Lancet 2010; 375: 132-
140.
34. Arnett DK, Khera A and Blumenthal RS. 2019 ACC/AHA
guideline on the primary prevention of cardiovascular disease:
part 1, lifestyle and behavioral factors. JAMA Cardiol 2019; 4:
1043-1044.
35. McCabe JJ, Walsh C, Gorey S, et al. C-reactive protein, interleukin-6,
and vascular recurrence after stroke: an individual
participant data meta-analysis. Stroke 2023; 54: 1289-1299.
36. Dehghan A, Dupuis J, Barbalic M, et al. Meta-analysis of
genome-wide association studies in >80 000 subjects identifies
multiple loci for C-reactive protein levels. Circulation
2011; 123: 731-738.
37. Georgakis MK, Malik R, Gill D, Franceschini N, Sudlow CLM
and Dichgans M. Interleukin-6 signaling effects on ischemic
stroke and other cardiovascular outcomes: a Mendelian randomization
study. Circ Genom Precis Med 2020; 13: e002872.
38. Papadopoulos A, Palaiopanos K, Björkbacka H, et al.
Circulating interleukin-6 levels and incident ischemic stroke:
a systematic review and meta-analysis of prospective studies.
Neurology 2022; 98: e1002-e1012.
39. Kamtchum-Tatuene J, Saba L, Heldner MR, et al. Interleukin-6
predicts carotid plaque severity, vulnerability, and progression.
Circ Res 2022; 131: e22-e33.
40. McCabe JJ, O'Reilly E, Coveney S, et al. Interleukin-6,
C-reactive protein, fibrinogen, and risk of recurrence after
ischaemic stroke: systematic review and meta-analysis. Eur
Stroke J 2021; 6: 62-71.
41. Gerard C and Rollins BJ. Chemokines and disease. Nat
Immunol 2001; 2: 108-115.
42. Georgakis MK, van der Laan SW, Asare Y, et al. Monocytechemoattractant
protein-1 levels in human atherosclerotic
lesions
associate
with
plaque
Thromb Vasc Biol 2021; 41: 2038-2048.
43. Georgakis MK, Malik R, Bjorkbacka H, et al. Circulating
monocyte chemoattractant protein-1 and risk of stroke: metaanalysis
of population-based studies involving 17 180 individuals.
Circ Res 2019; 125: 773-782.
44. Georgakis MK, Gill D, Rannikmae K, et al. Genetically
determined levels of circulating cytokines and risk of stroke.
Circulation 2019; 139: 256-268.
45. Boehme AK, McClure LA, Zhang Y, Luna JM, Del Brutto
OH, Benavente OR and Elkind MS. Inflammatory markers
and outcomes after lacunar stroke: levels of inflammatory
vulnerability. Arterioscler
WSO - April 2024

Table of Contents for the Digital Edition of WSO - April 2024
